Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged BioSpaceAfter devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioSpace After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BNext: FDA’s leadership void leaves biotech with renewed ‘uncertainty’ Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
